$44.86
1.0%
Downside
Day's Volatility :3.23%
Upside
2.24%
29.74%
Downside
52 Weeks Volatility :42.23%
Upside
17.78%
Period | Ultragenyx Pharmaceutical Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 1.85% | 6.5% | 0.0% |
6 Months | 0.2% | 7.1% | 0.0% |
1 Year | 6.93% | 9.8% | 0.0% |
3 Years | -43.22% | 14.2% | -20.2% |
Market Capitalization | 4.1B |
Book Value | $1.69 |
Earnings Per Share (EPS) | -7.95 |
PEG Ratio | -0.24 |
Wall Street Target Price | 89.65 |
Profit Margin | -138.58% |
Operating Margin TTM | -151.93% |
Return On Assets TTM | -26.97% |
Return On Equity TTM | -340.05% |
Revenue TTM | 442.6M |
Revenue Per Share TTM | 5.75 |
Quarterly Revenue Growth YOY | 8.3% |
Gross Profit TTM | -370.8M |
EBITDA | -550.8M |
Diluted Eps TTM | -7.95 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.54 |
EPS Estimate Next Year | -5.33 |
EPS Estimate Current Quarter | -1.73 |
EPS Estimate Next Quarter | -1.64 |
What analysts predicted
Upside of 99.84%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 51.5M | ↑ 1871.48% |
Net Income | -197.6M | ↓ 34.6% |
Net Profit Margin | -383.75% | ↑ 11183.59% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 103.7M | ↑ 101.41% |
Net Income | -402.7M | ↑ 103.8% |
Net Profit Margin | -388.31% | ↓ 4.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 271.0M | ↑ 161.32% |
Net Income | -186.6M | ↓ 53.67% |
Net Profit Margin | -68.84% | ↑ 319.47% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 351.4M | ↑ 29.66% |
Net Income | -454.0M | ↑ 143.36% |
Net Profit Margin | -129.2% | ↓ 60.36% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 363.3M | ↑ 3.39% |
Net Income | -707.4M | ↑ 55.81% |
Net Profit Margin | -194.71% | ↓ 65.51% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 434.2M | ↑ 19.52% |
Net Income | -606.6M | ↓ 14.25% |
Net Profit Margin | -139.7% | ↑ 55.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 103.3M | ↑ 13.94% |
Net Income | -151.8M | ↓ 38.05% |
Net Profit Margin | -146.91% | ↑ 123.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 100.5M | ↓ 2.76% |
Net Income | -164.0M | ↑ 7.99% |
Net Profit Margin | -163.16% | ↓ 16.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 108.3M | ↑ 7.77% |
Net Income | -159.8M | ↓ 2.53% |
Net Profit Margin | -147.57% | ↑ 15.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 98.1M | ↓ 9.47% |
Net Income | -159.6M | ↓ 0.11% |
Net Profit Margin | -162.82% | ↓ 15.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 127.4M | ↑ 29.92% |
Net Income | -123.2M | ↓ 22.84% |
Net Profit Margin | -96.7% | ↑ 66.12% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 108.8M | ↓ 14.57% |
Net Income | -170.7M | ↑ 38.55% |
Net Profit Margin | -156.83% | ↓ 60.13% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 719.6M | ↑ 46.62% |
Total Liabilities | 110.7M | ↑ 3.12% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 57.8% |
Total Liabilities | 481.7M | ↑ 335.37% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 54.96% |
Total Liabilities | 605.2M | ↑ 25.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↓ 13.48% |
Total Liabilities | 599.8M | ↓ 0.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 1.51% |
Total Liabilities | 1.2B | ↑ 98.88% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↓ 3.52% |
Total Liabilities | 1.2B | ↑ 1.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 4.51% |
Total Liabilities | 1.2B | ↑ 3.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 10.49% |
Total Liabilities | 1.2B | ↓ 2.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 5.21% |
Total Liabilities | 1.2B | ↑ 1.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 5.58% |
Total Liabilities | 1.2B | ↑ 2.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 20.42% |
Total Liabilities | 1.2B | ↑ 0.76% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 12.34% |
Total Liabilities | 1.2B | ↓ 4.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -290.6M | ↑ 14.47% |
Investing Cash Flow | -33.3M | ↓ 160.08% |
Financing Cash Flow | 336.9M | ↑ 147.2% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -345.4M | ↑ 18.87% |
Investing Cash Flow | -13.0M | ↓ 60.88% |
Financing Cash Flow | 679.3M | ↑ 101.66% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -132.2M | ↓ 61.72% |
Investing Cash Flow | -179.1M | ↑ 1273.73% |
Financing Cash Flow | 600.3M | ↓ 11.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -338.7M | ↑ 156.16% |
Investing Cash Flow | -195.4M | ↑ 9.07% |
Financing Cash Flow | 118.6M | ↓ 80.25% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -380.5M | ↑ 12.33% |
Investing Cash Flow | -291.7M | ↑ 49.28% |
Financing Cash Flow | 501.2M | ↑ 322.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -90.3M | ↓ 5.25% |
Investing Cash Flow | -171.6M | ↑ 6.02% |
Financing Cash Flow | 1.9M | ↓ 99.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -156.9M | ↑ 73.64% |
Investing Cash Flow | 111.3M | ↓ 164.86% |
Financing Cash Flow | -722.0K | ↓ 138.36% |
Sell
Neutral
Buy
Ultragenyx Pharmaceutical Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Ultragenyx Pharmaceutical Inc. | 11.18% | 0.2% | 6.93% | -43.22% | -27.61% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Ultragenyx Pharmaceutical Inc. | NA | NA | -0.24 | -6.54 | -3.4 | -0.27 | NA | 1.69 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Ultragenyx Pharmaceutical Inc. | Buy | $4.1B | -27.61% | NA | -138.58% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Ultragenyx Pharmaceutical Inc.
Revenue is down for the last 2 quarters, 127.39M → 108.83M (in $), with an average decrease of 14.6% per quarter
Netprofit is down for the last 2 quarters, -123.19M → -170.68M (in $), with an average decrease of 38.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 54.7%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 229.7%
Vanguard Group Inc
RTW INVESTMENTS, LLC
BlackRock Inc
Wellington Management Company LLP
Sands Capital Management, LLC
T. Rowe Price Associates, Inc.
Ultragenyx Pharmaceutical Inc.’s price-to-earnings ratio stands at None
Read Moreultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Organization | Ultragenyx Pharmaceutical Inc. |
Employees | 1276 |
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
Industry | Health Technology |
Outfront Media Inc.
$44.86
-0.44%
Blackrock Short Duration Bond Etf
$44.86
-0.44%
Moog Inc
$44.86
-0.44%
Edgio Inc.
$44.86
-0.44%
Invesco S&p 500 Momentum Etf
$44.86
-0.44%
Silicon Laboratories Inc
$44.86
-0.44%
Helmerich & Payne, Inc.
$44.86
-0.44%
Crane Nxt Co
$44.86
-0.44%
Liberty Global Plc - Class C Shares
$44.86
-0.44%